Chimerix Inc (STU:CXF)

€ 3.03 0.21 (7.45%) Market Cap: 298.58 Mil Enterprise Value: 168.48 Mil PE Ratio: 0 PB Ratio: 2.29 GF Score: 51/100

Q3 2024 Chimerix Inc Earnings Call Transcript
Nov 07, 2024

€0.855 (-10.19%)

Earnings
Q2 2024 Chimerix Inc Earnings Call Transcript
Aug 13, 2024

€0.689 (-6.64%)

Earnings
Q1 2024 Chimerix Inc Earnings Call Transcript
May 01, 2024

€0.856

Earnings
Q4 2023 Chimerix Inc Earnings Call Transcript
Feb 29, 2024

€1.12 (-7.95%)

Earnings
Q3 2023 Chimerix Inc Earnings Call Transcript
Nov 02, 2023

€0.8992 (+2.51%)

Earnings
Q2 2023 Chimerix Inc Earnings Call Transcript
Aug 03, 2023

€1.04

Earnings
Chimerix Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Chimerix Inc Earnings Call Transcript
May 04, 2023

€1.02 (-0.44%)

Earnings
Q4 2022 Chimerix Inc Earnings Call Transcript
Mar 02, 2023

€1.55 (+6.01%)

Earnings
Chimerix Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 Chimerix Inc Earnings Call Transcript
Nov 03, 2022

€1.82 (-4.55%)

Earnings
Q2 2022 Chimerix Inc Earnings Call Transcript
Aug 08, 2022

€2.26 (-10.79%)

Earnings
Q1 2022 Chimerix Inc Earnings Call Transcript
May 16, 2022

€2.04 (-41.86%)

Earnings
Q4 2021 Chimerix Inc Earnings Call Transcript
Mar 01, 2022

€4.87 (-1.78%)

Earnings
Chimerix Inc to Discuss Positive ONC201 Data in Recurrent H3 K27M-mutant Diffuse Midline Glioma Call Transcript
Nov 22, 2021
Chimerix Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 08, 2021
Q3 2021 Chimerix Inc Earnings Call Transcript
Nov 04, 2021

€5.21 (+4.73%)

Earnings
Q2 2021 Chimerix Inc Earnings Call Transcript
Aug 05, 2021

€5.57 (+4.90%)

Earnings
Chimerix Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021
Q1 2021 Chimerix Inc Earnings Call Transcript
May 06, 2021

€6.6 (-11.06%)

Earnings
Q4 2020 Chimerix Inc Earnings Call Transcript
Feb 25, 2021

€8.48 (+3.41%)

Earnings
Chimerix Inc to Acquire Oncoceutics Inc - Conference Call Transcript
Jan 08, 2021
Chimerix Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 12, 2020
Q3 2020 Chimerix Inc Earnings Call Transcript
Nov 05, 2020

€2.5 (+0.81%)

Earnings
Q2 2020 Chimerix Inc Earnings Call Transcript
Aug 10, 2020

€2.68

Earnings
Chimerix Inc DSTAT Clinical Update Conference Call Transcript
Apr 29, 2020
Q4 2019 Chimerix Inc Earnings Call Transcript
Feb 25, 2020

€1.71 (+11.76%)

Earnings
Chimerix Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 13, 2019
Q3 2019 Chimerix Inc Earnings Call and Operational Updates Transcript
Nov 05, 2019

€1.39 (-2.11%)

Earnings
Chimerix Inc CX-01 Call Transcript
Jul 31, 2019
Q1 2019 Chimerix Inc Earnings Call Transcript
May 09, 2019

€2.5 (+6.38%)

Earnings
Q4 2018 Chimerix Inc Earnings Call Transcript
Mar 05, 2019

€1.8 (-8.16%)

Earnings

Q3 2021 Chimerix Inc Earnings Call Transcript

Nov 04, 2021 / 12:30PM GMT

Release Date Price: €5.21 (+4.73%)

Transcript 10-Q8-K

Operator

Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2021 Earnings Conference Call.

I would now like to introduce you to your host for today's call, Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix. Please proceed.

Michelle LaSpaluto

Chimerix, Inc. - VP of Strategic Planning & IR

Thank you. Good morning, everyone, and welcome to the Chimerix Third Quarter 2021 Financial and Operating Results Conference Call. This morning, we issued our third quarter financial results press release and a separate release reporting positive top line results from the ONC201 recurrent H3 K27M-mutant glioma. You can access those press releases in our Investor Relations section of the website.

With me on today's call are President and Chief Executive Officer, Mike Sherman; Chief Financial and Business Officer, Mike Andriole; Allen Melemed, our Chief Medical Officer; and Josh Allen, our Chief Technology Officer of Imipridones.

Before we begin, I would like to remind you that the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.